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Purpose: There is increasing interest in personalized prediction of disease progression for soft tissue sarcoma
patients. Currently, available prediction models are limited to predictions from time of surgery or diagnosis. This
study updates predictions of overall survival at different times during follow-up by using the concept of dynamic
prediction.
Patients and methods: Information from 2232 patients with high-grade extremity soft tissue sarcoma, who un-
derwent surgery at 14 specialized sarcoma centers, was used to develop a dynamic prediction model. The model
provides updated 5-year survival probabilities from different prediction time points during follow-up. Baseline
covariates as well as time-dependent covariates, such as status of local recurrence and distant metastases, were
included in the model. In addition, the effect of covariates over time was investigated and modelled accordingly
in the prediction model.
Results: Surgical margin and tumor histology show a significant time-varying effect on overall survival. The
effect of margin is strongest shortly after surgery and diminishes slightly over time. Development of local re-
currence and distant metastases during follow-up have a strong effect on overall survival and updated predic-
tions must account for their occurrence.
Conclusion: The presence of time-varying effects, as well as the effect of local recurrence and distant metastases
on survival, suggest the importance of updating predictions during follow-up. This newly developed dynamic
prediction model which updates survival probabilities over time can be used to make better individualized
treatment decisions based on a dynamic assessment of a patient's prognosis.
1. Introduction
High-grade soft tissue sarcomas (STS) are highly aggressive tumors
with poor prognosis [1,2]. Soft tissue sarcomas of the extremities ac-
count for approximately 60% of all STS diagnoses [3]. The effect of
prognostic factors measured at the time of surgery (e.g. age, surgical
margin, radiotherapy, tumor size, depth, and histology subtype) on
overall survival has been previously investigated [1–6] and is used in
the form of prediction tools such as nomograms and online applications
to make patient-specific predictions of disease progression [4,5]. The
continuous prediction of OS during treatment and follow-up has proven
its clinical benefit in shared decision making and choosing the optimal
individualized treatment strategy in several carcinoma cohorts [7–9].
A weakness of current sarcoma models is that they are designed for
use at baseline, such as at the time of diagnosis or surgery, and cannot
be used to make adequate predictions at later time points during follow-
up. After surgery approximately 10% of high grade STS patients de-
velop local recurrence (LR) with or without synchronous distant
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metastases (DM). Both will have a significant impact on future disease
progression and the difference in prognosis should be incorporated in
future treatment protocols. Even the fact that a patient survived a
length of time after surgery might give an indication about his future
prognosis. In addition, the effect of prognostic factors may change over
time (time-varying effect), which has not yet been studied. For ex-
ample, surgical margin and radiotherapy might have a strong impact on
survival in the immediate time after surgery; however, their effect may
change during follow-up. The use of time-dependent covariates, such as
LR and DM status, and time-varying effects to update survival prob-
abilities during follow-up is known as dynamic prediction [10]. To the
best of our knowledge, no previous prediction model has been pub-
lished taking the time-varying effect of risk factors into account for
patients with STS. This study fills a gap in current research by in-
vestigation the effect of risk factors for death in high-grade extremity
STS patients over time.
The aim of this study was to develop a dynamic prediction model for
high-grade (FNCLCC grade II and III [11]) extremity STS patients that
updates overall survival probabilities during follow-up. The effect of
prognostic factors over time was studied and modelled accordingly in
the dynamic model. The model predicts a patient's probability of sur-
viving an additional five years from different prediction time points (tp)
after resection of their sarcoma. Specific patient examples are used to
illustrate how predicted probabilities change at different prediction
time points during follow-up. To implement these findings in clinical
practice, this model will be made available in the updated PERSARC
app and online [4].
2. Methods
2.1. Study design
In this study a dynamic prediction model, using a retrospectively
collected cohort of patients with STS of the extremities, was developed
and internally validated. Clinical data were collected between January
1st, 2000 and December 31st, 2014, at 14 different international spe-
cialized sarcoma centers, thereby creating the largest multinational
dataset of high-grade surgically treated extremity STS patients in the
world. Included centers are Leiden University Medical Center (Leiden,
the Netherlands), Royal Orthopaedic Hospital (Birmingham and
Stanmore, UK), Netherlands Cancer Institute (Amsterdam, the
Netherlands), Mount Sinai Hospital (Toronto, Canada), the Norwegian
Radium Hospital (Oslo, Norway), Aarhus University Hospital (Aarhus,
Denmark), Skåne University Hospital (Lund, Sweden), and Medical
University Graz (Graz, Austria). The outcome measure used was overall
survival, which was defined as time from surgery to death from any
cause or last recorded follow-up. The prediction model estimates the
dynamic probability of surviving an additional five years from a pre-
diction time point tp called dynamic overall survival (DOS). From time
of surgery predictions of 5-year DOS can be estimated based on updated
patient information.
Table 1
Patient demographics.
Characteristics Overall
Total 2232
Age mean (sd) 60.86 (18.74)
Gender (%) Male 1203 (53.9)
Female 1029 (46.1)
Tumor size in cm mean (sd) 8.95 (5.85)
Tumor depth (%) Deep 1269 (56.9)
Superficial 551 (24.7)
Unknown 412 (18.5)
Histology (%) Myxofibrosarcoma 432 (19.4)
MPNST 167 ( 7.5)
Synovial sarcoma 277 (12.4)
Sarcoma – NOS 108 ( 4.8)
Spindle cell sarcoma 492 (22.0)
MFH/UPS 604 (27.1)
Other 152 ( 6.8)
Margin (%) R1-2 274 (12.3)
R0 1890 (84.7)
Unknown 68 ( 3.0)
Radiotherapy (%) No radiotherapy 916 (41.0)
Neoadjuvant 265 (11.9)
Adjuvant 1004 (45.0)
Unknown 47 ( 2.1)
Chemotherapy (%) No chemotherapy 1876 (84.1)
Neoadjuvant 98 ( 4.4)
Adjuvant 228 (10.2)
Unknown 30 ( 1.3)
N, number of patients; sd, standard deviation; cm, centimeters; MPNST, ma-
lignant peripheral nerve sheath tumor; sarcoma – NOS, (pleomorphic) soft
tissue sarcomas not-otherwise-specified; MFH/UPS, malignant fibrous histio-
cytoma/undifferentiated pleomorphic sarcoma; Histology “Other”, angio-
sarcoma, leiomyosarcoma, liposarcoma, malignant rhabdoid tumor, alveolar
soft part sarcoma, epithelioid sarcoma, clear cell sarcoma, rhabdomyosarcoma
(adult form) and conventional fibrosarcoma. aDepth: relative to the investing
fascia.
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Fig. 1. Number of patients at risk at each landmark time point tLM. A) Red, patients with local recurrence; blue, patients without local recurrence. B) Red, patients
with distant metastases; blue, patients without distant metastases.
A.J. Rueten-Budde et al. Surgical Oncology 27 (2018) 695–701
696
2.2. Patients and variables
Ethical approval for this study was waived by the institutional re-
view board, because clinical data was collected from medical records.
Patients were selected from each hospital's own sarcoma registry based
on histological diagnosis. Eligible diagnoses included high-grade
(FNCLCC grade II and III [11]) angiosarcoma, malignant peripheral
nerve sheath tumor (MPNST), synovial sarcoma, spindle cell sarcoma,
myxofibrosarcoma, liposarcoma, leiomyosarcoma, malignant fibrous
histiocytoma/undifferentiated pleomorphic sarcoma (MFH/UPS),
(pleomorphic) soft tissue sarcomas not-otherwise-specified (NOS), ma-
lignant rhabdoid tumor, alveolar soft part sarcoma, epithelioid sar-
coma, clear cell sarcoma, rhabdomyosarcoma (adult form) and
conventional fibrosarcoma. Patients were excluded if they were initially
treated without curative intent, presented with LR or DM, had Kaposi's
or rhabdomyosarcoma (pediatric form), had a tumor in their abdomen,
thorax, head or neck, or received isolated limb perfusion as (neo-)ad-
juvant treatment. For follow-up all collaborating sarcoma centers ad-
hered to the guidelines of the European Society for Medical Oncology
[12].
In the following, baseline and time-dependent variables that were
included into the dynamic model are defined. Predictors measured at
baseline were: age (years), tumor size by the largest diameter measured
at pathological examination (centimeters), tumor depth in relation to
investing fascia (deep/superficial), and histological subtype according
to WHO classification [13]. Radiotherapy (yes/no) was further speci-
fied as being either neoadjuvant or adjuvant treatment. Chemotherapy
was not included in the model because it was seldom given to patients
for primary tumors. Surgical margins were categorized according to the
categorical R-system: ‘R0’ for a negative margin and ‘R1-2’ for a positive
margin with tumor cells in the inked surface of the resection margin
[14]. The potential effect modifier grade was not included, since all
included patients had high-grade tumors. Local recurrence was defined
as the presence of pathologically and/or radiologically confirmed
tumor at the site where it was originally detected, more than two
months after primary surgery. Distant metastases were defined as
radiological evidence of systemic spread of tumor distant from the
primary tumor site.
Initially 2427 patients were considered, however, those who un-
derwent surgery before January 1st, 2000 (n=187) and those with
missing outcome information (n=8) were excluded leaving a total of
2232 patients for analysis.
2.3. Statistical analysis
To estimate a prediction model for 5-year DOS a proportional
landmark supermodel was used [10,15]. A landmark model is able to
make predictions from a particular landmark time tLM, by using all
(updated) information of patients in follow-up at that time. A landmark
supermodel combines several landmark models corresponding to dis-
tinct landmark time points to make predictions at different prediction
times tp during follow-up.
To fit such a model, landmark time points tLM were chosen every
three months between zero and five years after surgery. At each of these
time points a Cox proportional hazards model was estimated on the
subset of patients still at risk: patients alive and in follow-up at time tLM.
The status of LR and DM is determined at landmark time point tLM for
each patient and considered fixed. These Cox models were then com-
bined into a landmark supermodel.
The main covariates as well as the linear and quadratic effect of
time in form of the term tLM and tLM2 were included into the model.
Some histology subtypes were not sufficiently represented in the data
(n≤ 35) and it was not possible to estimate a separate effect for them
on survival. For this reason, they were grouped together under the label
“Other”.
A backward selection procedure was used to select further time-
varying covariates. The time-varying effect of a covariate is modelled
by the interaction term between the covariate and time. Initially all
interactions of covariates with tLM and tLM2 were included in the model,
after which interactions with tLM2 without significant effect were re-
moved. In the next step, interactions for these prognostic factors with
tLM were considered and removed from the model if they had no sig-
nificant effect. A p-value of ≤0.05 was considered significant.
The validity of the prediction model was assessed in terms of model
calibration, which refers to how well predicted probabilities agree with
observed probabilities. The model was internally calibrated using the
heuristic shrinkage factor [16]. Shrinkage of a linear prognostic index
towards the mean can improve the predictions of a prognostic model
[15]. The estimated shrinkage factor on new data is an estimate of
Table 2
Dynamic prediction model for overall survival: hazard ratio (HR) along with
95% confidence interval (n= 2232).
HR 95% CI P-value
Covariates with time-constant effects
Age (ref: 60 years, per 10 years)
Age 1.444 1.381–1.510 < 0.001
Age2 1.065 1.048–1.082 < 0.001
Tumor size (ref: 0 cm, per 1 cm)
Size 1.120 1.072–1.169 < 0.001
Size2 0.997 0.996–0.999 0.002
Tumor depth (superficial vs. deep) 0.784 0.654–0.940 0.020
Radiotherapy (RT)
No RT 1
Neoadjuvant 0.773 0.572–1.044 0.095
Adjuvant 0.903 0.763–1.068 0.238
Local recurrence (yes vs. no) 1.998 1.622–2.461 < 0.001
Distant metastasis (yes vs. no) 7.572 6.501–8.818 < 0.001
Covariates with time-varying effects
Prediction time (ref: time of surgery, per year)
tp 0.431 0.330–0.562 < 0.001
tp2 1.127 1.066–1.192 < 0.001
Histology
Constant
Myxofibrosarcoma 1
MPNST 1.807 1.270–2.571 0.001
Synovial sarcoma 1.323 0.971–1.801 0.076
Sarcoma – NOS 1.181 0.784–1.781 0.426
Spindle cell sarcoma 0.819 0.638–1.051 0.117
MFH/UPS 1.000 0.789–1.269 0.974
Other 1.229 0.828–1.825 0.307
Linear time-varying effect
Myxofibrosarcoma 1
MPNST 0.916 0.692–1.212 0.539
Synovial sarcoma 1.368 1.084–1.727 0.008
Sarcoma – NOS 1.067 0.739–1.540 0.730
Spindle cell sarcoma 1.184 0.959–1.461 0.116
MFH/UPS 1.256 1.024–1.540 0.029
Other 1.050 0.742–1.486 0.781
Quadratic time-varying effect
Myxofibrosarcoma 1
MPNST 0.985 0.930–1.044 0.618
Synovial sarcoma 0.913 0.864–0.964 0.001
Sarcoma – NOS 0.983 0.913–1.058 0.648
Spindle cell sarcoma 0.990 0.947–1.035 0.660
MFH/UPS 0.968 0.928–1.010 0.137
Other 0.985 0.913–1.062 0.689
Margin
Constant
R0 vs. R1-2 0.764 0.606–0.964 0.024
Linear time-varying effect
R0 vs. R1-2 1.417 1.127–1.783 0.003
Quadratic time-varying effect
R0 vs. R1-2 0.947 0.902–0.993 0.026
HR, hazard ratio; CI, confidence interval; tp, prediction time points; MPNST,
malignant peripheral nerve sheet tumor; sarcoma – NOS, (pleomorphic) soft
tissue sarcomas not-otherwise-specified; MFH/UPS, malignant fibrous histio-
cytoma/undifferentiated pleomorphic sarcoma. aDepth: relative to the in-
vesting fascia.
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necessary calibration needed to improve the model fit on new data.
Without an external data set the shrinkage factor can be determined
using a heuristic formula and may take values between zero and one,
where values close to one represent a good calibration.
Model discrimination refers to the ability of the model to predict
higher risks for patients with an early event compared to those with
later or no event and was assessed using the dynamic cross-validated C-
index [15]. A C-index equal to one means that the model has perfect
discrimination and a C-index of 0.5 means that the model predicts just
as well as flipping a coin [17].
Most statistical methods are not able to include observations with
missing values, which leads to the removal of patients with missing
information. To make optimal use of the collected data multiple im-
putation was applied. The R-package Amelia II was used to impute five
complete data sets with plausible values [18]. Across these data sets
observed values stay the same, however missing values were inserted
with a distribution that reflects the uncertainty surrounding the missing
data. Statistical methods were applied to each individual complete data
set and the results were then combined following Rubin's rule [19]. The
analysis was adjusted for country effect by including country as a fixed
covariate into the model. The items on both the checklist of
STrengthening the Reporting of OBservational studies in Epidemiology
(STROBE) and the Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis (TRIPOD) we considered
during model development [20,21]. All statistical analyses were
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Fig. 2. 5-year probability of death estimates for patients with different characteristics and at different states of disease progression. A and B: 61 years, tumor of 9 cm,
deep myxofibrosarcoma, treated with an R0 margin and no radiotherapy. (A) Without DM at time of prediction (tp). (B) diagnosed with DM before time of prediction
(tp). C and D: 45 years, 5 cm superficial synovial sarcoma, treated with an R0 margin, and adjuvant radiotherapy. (C) Without DM at time of prediction (tp). (D)
diagnosed with DM before time of prediction (tp). Blue: without LR; red: with LR.
Table 3
Values of HR for 5-year dynamic overall survival for a patient operated with an
R0 margin at different prediction time points tp (reference: R1-2).
tp constant linear time-
varying effect
quadratic time-
varying effect
HR 95% CI P-value
0 0.764 1.4170 0.9470 0.764 0.606–0.964 0.024
1 0.764 1.4171 0.9471 1.025 0.828–1.269 0.821
2 0.764 1.4172 0.9474 1.234 0.943–1.614 0.128
3 0.764 1.4173 0.9479 1.332 0.965–1.838 0.085
4 0.764 1.4174 0.94716 1.289 0.859–1.934 0.232
5 0.764 1.4175 0.94725 1.119 0.628–1.992 0.730
tp prediction time point; HR, hazard ratio; CI, confidence interval.
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performed in the R-software environment [22].
3. Results
The number of patients used for this analysis was 2232, with a
median follow-up of 6.42 years (95% confidence interval: 6.17–6.72),
assessed with the reverse Kaplan-Meier method [23]. Table 1 provides a
summary of the patient characteristics.
An overview of the number of patients used at each landmark time
point is given in Fig. 1 together with information about their disease
status at that time. In total 1034 patients died, 143 patients developed
LR, 556 DM, and 159 developed both.
Table 2 shows hazard ratios (HR) together with 95% confidence
intervals (95%CI) for the risk factors included in the Cox proportional
hazard model. Hazard ratios for covariates with time-constant and
time-varying effects are shown in the upper and lower part of the table
respectively.
Age, tumor size, and depth show a significant time-constant effect
on 5-year DOS. Age and tumor size are modelled by both a linear and
quadratic term (age in steps of 10 years, size in cm), due to significant
nonlinearity. The HR corresponding to a particular age and size consists
of two components: their linear effect HRlin and their quadratic effect
HRquad. For the risk factor age the HR of a 70-year-old patient compared
to a 60-year-old patient (reference) is equal to
× = × =HR HR 1.444 1.065 1.538linstep quadstep2
where ‘step’ in the computation represents the age difference between
the two patients, and one step corresponds to a 10-year increase.
The HR of an 80-year-old patient (20-year increase, corresponding
to a step of 2) compared to a 60-year-old one is equal to
1.4442×1.0654=2.682.
Both LR and DM show a significant time-constant effect with HR
equal to 1.998 (95%CI: 1.622–2.461) and 7.572 (95%CI: 6.501–8.818)
respectively. The occurrence of LR significantly decreases the 5-year
DOS predictions (Fig. 2). Fig. 2 shows the probability of dying within
five years for patients with different baseline characteristics and states
of disease progression, from different prediction time points tp. In
Fig. 2A the probability of dying within five years is displayed for two
61-year old patients with 9 cm deep myxofibrosarcoma, R0 margin, no
radiotherapy treatment and no DM. The blue and red lines represent the
probability of dying within five years for patients with the previous
characteristics in the absence and presence of LR at prediction time
point tp respectively. If still alive at one year after surgery, the prob-
ability of dying within five years is 30% and 52% for the patient
without and with LR respectively. Fig. 2B shows that patients with the
same risk factors as individuals in Fig. 2A who developed DM before the
prediction time point tp have a much higher dynamic prediction of
death within five years. Fig. 2C and D illustrate a very different pre-
diction pattern for a patient with other characteristics.
Surgical margin and histology subtype show a significant time-
varying effect. To explain how the time component is incorporated in
the model and affects a patient's risk, the HR at one year after surgery
for a patient with an R0 margin compared to a patient with an R1-2
margin is calculated by using the following formula
= ××= × × =
HR [constant (linear time varying effect)
(quadratic time varying effect) ]
0.764 1.417 0.947 1.025
t
t
p
p2
where tp= 1 and tp2= 1 (Table 3).
The HR changes from 0.764 at time of surgery to 1.025 one year
after surgery. At a prediction time point of two years after surgery, the
HR further increases to 1.234. The change in HRs over time for margin
is depicted in Fig. 3. The figure shows that an R0 margin right after
surgery appears to have a protective effect on 5-year DOS. However, the
effect decreases with time.
The (time-varying) effect of histology subtype may be calculated
analogously to the margin example. The interpretation of its effect
however, is more difficult since all HRs are given relative to the chosen
reference category myxofibrosarcoma.
Fig. 4 displays the time-varying effect of histology subtype on two
example patients. The left panels (A, C, and E) display the 5-year
probability of death for a 61 year old patient with a 9 cm deep tumor,
treated with no radiotherapy and R0 margin. Panel A shows the prob-
abilities in case this specific patient had no adverse event at time of
prediction. Panel C and E show the probabilities of death in case the
patient had LR or DM at time of prediction respectively. Different
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colored lines correspond to different histology subtypes. Analogously,
the left panels (B, D, and F) show probabilities for a 45 year old patient
with 5 cm superficial tumor, treated with adjuvant radiotherapy and R0
margin.
Good model calibration was indicated by a heuristic shrinkage
factor equal to 0.996. The discriminative ability of the model was
measured with dynamic cross-validated C-indices of 0.694, 0.777,
0.813, 0.810, 0.798, and 0.781 at 0-, 1-, 2-, 3-, 4-, and 5-years after
surgery respectively. The C-indices are quite high, implying a very good
discriminative ability of the model. The reason for this is the strong
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Fig. 4. 5-year probability of death estimates for patients with different characteristics and at different states of disease progression. A, C, and E: 61 years, 9 cm deep
tumor, with R0 margin and no radiotherapy. (A) Without LR or DM at time of prediction (tp). (C) diagnosed with LR before time of prediction (tp). (E) diagnosed with
DM before time of prediction (tp). B, D, and F: 45 years, 5 cm superficial tumor, with R0 margin and adjuvant radiotherapy. (B) Without LR or DM at time of
prediction (tp). (D) diagnosed with LR before time of prediction (tp). (F) diagnosed with DM before time of prediction (tp).
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predictive value that DM has for survival. A patient with DM will have a
much worse prognosis compared to a patient without DM.
4. Discussion
The prediction model developed in this study is able to provide
estimates for the probability of surviving an additional five years from a
prediction time point after surgery (tp). It can be used from time of
surgery up until five years post-surgery to make updated predictions for
patients with high-grade STS of the extremities treated surgically with
curative intent. This allows for optimization of evidence based shared
decision-making and may improve the personalization of sarcoma
treatment. Information about a patient's LR and DM status is used in the
model, since those factors significantly influence a patient's prognosis.
Additionally, it allows for personalization of the treatment options in
progressive disease. Internal calibration using the heuristic shrinkage
factor showed that the model was well calibrated and dynamic cross-
validated C-indices demonstrate its ability to discriminate between
high- and low-risk patients.
Additionally, this study investigated the effect of prognostic factors
over time and found a significant time-varying effect for surgical
margin and histology subtype on overall survival. Initially an R0 margin
is associated with a better 5-year DOS compared to an R1-2 margin,
however, this effect changes over time. At later time points during
follow-up, no significant effect of margin on 5-year DOS could be found.
This result should be interpreted with caution since the majority of
patients were treated with (neo)adjuvant radiotherapy (see Table 1).
The strength of this research is that the data were collected from a
very large number of relatively homogeneous sarcoma patients world-
wide and patients were not selected (i.e. this is a ‘real world’ patient
population). A limitation of this study is that re-evaluations of tumor
histology could not be performed due to practical and logistical con-
straints. Additionally, when a patient has developed DM and/or is re-
ceiving care in the palliative setting, the routine checks for LR are not
always performed and therefore underestimation of the total incidence
of LR might be possible.
To the best of the authors’ knowledge, this is the first dynamic
prediction model for patients with high-grade extremity STS, which
allows for prediction of 5-year DOS during follow-up. A similar model
has been used to make dynamic predictions for breast cancer patients
[24]. This model is an essential addition to current models, since it
provides updated predictions after surgery (instead of at the time of
surgery alone).
The results of this study will be made freely available through the
updated PERsonalized SARcoma Care (PERSARC) mobile application.
With the app it will be possible to make personalized dynamic predic-
tions during follow-up, taking specific patient, tumor, and treatment
characteristics into account [4].
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